Loading
Journal of Allergy and Infectious Diseases
ISSN: 2692-6334


H James Wedner
Professor
Washington University, USA
Chemical characterization of red imported fire ants with colony development
Mitochondrial disease patients and rotavirus infection complications
Building and implementing best practices for referral and management of severe asthma in Canadian healthcare
Journal of Allergy & Infectious Diseases is an international peer reviewed open access journal that publishes articles related to allergy & infectious diseases. It presents a spectrum of exciting information on various approaches adopted and their possible outcomes in allergy and inflammation research including new strategies in diagnosis, therapy and prevention of allergic and infectious diseases. The journal publishes high quality papers, which cover the entire major field related to allergy and infectious diseases.
Brucellosis as a cause of acute-on-chronic liver failure in a person with advanced HIV disease and HBV reactivation: a case report
Brucellosis is a zoonosis in which hepatic involvement is common but usually mild. Acute liver failure and acute-on-chronic liver failure (ACLF) are rarely attributed to brucellosis, and even more rarely to people living with HIV (PLWH).
Near-point-of-care molecular HPV diagnostics: Pathways to scalable cervical-cancer screening in low-and middle-income countries
Cervical cancer remains a leading cause of preventable death among women. Around 660,000 new cases and 350,000 deaths were reported in 2022. Most of these cases and deaths occurred in low- and middle-income countries. Persistent infection with oncogenic human papillomavirus (HPV) genotypes is an important cause of almost all cervical cancers.
Control of epidemics: Testing, vaccinations, and monitoring
Increasing the test-per-case ratio was recommended to reduce the number of cases and deaths per capita. In particular, due to a synchronous increase in the number of tests alongside the rise in new cases and very high levels of the tests-per-case ratio, the COVID-19 pandemic in New Zealand was largely controlled before October 2021. After February 2022, an abrupt decline in the tests-to-case ratio led to a record number of cases and deaths at a relatively high vaccination level.
Reframing women’s vulnerability through a gendered and structural lens: Women economic empowerment as an HIV prevention strategy
Women and girls continue to experience disproportionate HIV vulnerability across regions marked by deep-rooted gender inequality and economic insecurity. While biomedical advances have expanded prevention options, the structural determinants particularly poverty, economic dependence and limited financial autonomy remain under-addressed drivers of HIV risk.
Chemical characterization of red imported fire ants with colony development
The red imported fire ant, Solenopsis invicta Buren, poses a significant threat to public health due to its venomous stings. While the chemistry of fire ants has been well investigated, most studies have focused on ants from mature colonies. The dynamic changes in chemical compositions during colony development have been less explored. In this study, we established S. invicta colonies using newly collected queens from the field and then tracked the chemistry of workers as the colonies developed. Our findings reveal that the chemistry of fire ant workers undergoes significant changes with the development of the colonies. However, the change in chemical diversity was not necessarily in the same direction for all individual glands.
Mitochondrial disease patients and rotavirus infection complications
Rotavirus (RV) is an agent of gastroenteritis and, to a lesser extent, neurological manifestations including seizures and epilepsy. Before the development of effective vaccines, rotavirus was among the leading global drivers of life-threatening diarrhea in neonates and children less than five years of age.
Building and implementing best practices for referral and management of severe asthma in Canadian healthcare
Severe asthma (SA) is asthma that remains uncontrolled despite patient adherence to mainteneance therapies and management of contributing factors, or asthma which worsens when high-dose treatments are reduced. It is estimated that 5-10% of asthma patients in Canada have SA. The condition is a significant burden on patients’ quality of life, and is associated with increased number and severity of exacerbations, hospitalizations, and mortality
Possible therapeutic targets for SARS-CoV-2 infection and COVID-19
SARS-CoV-2 infection causes COVID-19, which has emerged as a health emergency worldwide. SARS-CoV-2 infects cells by binding to ACE2 receptors and enters into the cytoplasm following its escape from endolysosomes. Once in the cytoplasm, the virus replicates and eventually causes various pathological conditions including acute respiratory distress syndrome (ARDS) that is caused by pro-inflammatory cytokine storms.
Monitoring clinical trials in infectious diseases
In early 2020, the contagious and deadly virus, SARS-CoV-2, was identified. The virus spread rapidly worldwide and was declared a pandemic by the World Health Organization (WHO) in March of 2020 [1]. While many who became infected remained asymptomatic, an alarming number of infected individuals developed severe symptoms, often requiring hospitalization and intensive care, or resulting in death.
Policy and law changes to address healthcare inequities for minority populations during COVID-19
While other countries have begun to see a flattening of the Severe Acute Respiratory Syndrome – Coronavirus-2 (SARS-CoV-2) curve, the United States continues to see a rise in cases, with approximately 7.4 million confirmed cases to date. Even more worrisome, various news articles have begun to shed light on the healthcare inequities that have become increasingly more transparent during this crisis.
Building and implementing best practices for referral and management of severe asthma in Canadian healthcare
Severe asthma (SA) is asthma that remains uncontrolled despite patient adherence to mainteneance therapies and management of contributing factors, or asthma which worsens when high-dose treatments are reduced. It is estimated that 5-10% of asthma patients in Canada have SA. The condition is a significant burden on patients’ quality of life, and is associated with increased number and severity of exacerbations, hospitalizations, and mortality
Possible therapeutic targets for SARS-CoV-2 infection and COVID-19
SARS-CoV-2 infection causes COVID-19, which has emerged as a health emergency worldwide. SARS-CoV-2 infects cells by binding to ACE2 receptors and enters into the cytoplasm following its escape from endolysosomes. Once in the cytoplasm, the virus replicates and eventually causes various pathological conditions including acute respiratory distress syndrome (ARDS) that is caused by pro-inflammatory cytokine storms.
Monitoring clinical trials in infectious diseases
In early 2020, the contagious and deadly virus, SARS-CoV-2, was identified. The virus spread rapidly worldwide and was declared a pandemic by the World Health Organization (WHO) in March of 2020 [1]. While many who became infected remained asymptomatic, an alarming number of infected individuals developed severe symptoms, often requiring hospitalization and intensive care, or resulting in death.
Policy and law changes to address healthcare inequities for minority populations during COVID-19
While other countries have begun to see a flattening of the Severe Acute Respiratory Syndrome – Coronavirus-2 (SARS-CoV-2) curve, the United States continues to see a rise in cases, with approximately 7.4 million confirmed cases to date. Even more worrisome, various news articles have begun to shed light on the healthcare inequities that have become increasingly more transparent during this crisis.
Mitochondrial disease patients and rotavirus infection complications
Rotavirus (RV) is an agent of gastroenteritis and, to a lesser extent, neurological manifestations including seizures and epilepsy. Before the development of effective vaccines, rotavirus was among the leading global drivers of life-threatening diarrhea in neonates and children less than five years of age.
Monitoring clinical trials in infectious diseases
In early 2020, the contagious and deadly virus, SARS-CoV-2, was identified. The virus spread rapidly worldwide and was declared a pandemic by the World Health Organization (WHO) in March of 2020 [1]. While many who became infected remained asymptomatic, an alarming number of infected individuals developed severe symptoms, often requiring hospitalization and intensive care, or resulting in death.
Policy and law changes to address healthcare inequities for minority populations during COVID-19
While other countries have begun to see a flattening of the Severe Acute Respiratory Syndrome – Coronavirus-2 (SARS-CoV-2) curve, the United States continues to see a rise in cases, with approximately 7.4 million confirmed cases to date. Even more worrisome, various news articles have begun to shed light on the healthcare inequities that have become increasingly more transparent during this crisis.